CoLucid Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
CoLucid Pharmaceuticals starts out with an in-licensed migraine drug from Eli Lilly, one of a new class of molecules known as neurally acting anti-migraine agents. The phase II drug has demonstrated equal efficacy to triptans in the control of migraine symptoms without triptans' risk of cardiovascular side effects. CoLucid is also developing a wake-promotion drug using technology licensed from Sention.
You may also be interested in...
Start-Up Previews (09/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.
Homology Medicines Inc.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.